OUTCOMES AND COMPLICATIONS OF ANTI-PD-1 IMMUNOTHERAPY COMBINED WITH SURGERY FOLLOWING CHEMOTHERAPY IN ATHLETES WITH NON-SMALL CELL LUNG CANCER

Abstract

Objective: The goal of this research is to investigate the efficacy and adverse reactions of post-chemotherapy surgery followed by anti-programmed death factor (PD-1) immune therapy for the treatment of non-small cell lung cancer (NSCLC). Method: A random number table was used to pick 92 athletic patients with NSCLC admitted to our hospital between January 2019 and August 2021, and split them evenly into a control group (n = 46) and an observation group (n = 46). In which the control was received conventional chemotherapy intervention, whereas the observation group was given nivolumab based on the results of the control group. Surgery was used in both groups. Result: Total effectiveness in the observation group was 69.57%, which was statistically substantially greater than the control group's 32.61% (P <0.05). After therapy, significant increases in CD3+ level and in the ratio of CD3+/CD4+ were seen in both groups compared with those before therapy, whereas a decrease in the ratio of CD4+/CD125+ was observed. And after treatment, the ratio of CD3+/CD125+ was substantially lower in the observation group compared to the control group, CD3+ level and the ratio of CD3+/CD4+ were substantially greater in the observation group compared to the control group (P <0.05). Compared with the blood CEA, CA125, and CYFRA21-1 levels before therapy, both groups saw a substantial decrease after therapy (P <0.05). Levels of serum CEA, CA125, and CYFRA21-1 were all substantially reduced in the observation group compared to the control group after therapy (P <0.05). Levels of IFN- γ 、TNF- α were considerably up-regulated, whereas levels of IL-10 and IL-6 in the serum were dramatically reduced after treatment compared to the levels before therapy in both groups. Serum IL-10 and IL-6 levels in the observation group were considerably lower than those in the control group after treatment, whereas IFN-γ、TNF-α levels were significantly increased (P <0.05). When compared to the control group, the incidence of adverse responses was 43.48 % lower in the observation group (P <0.05). Twelve months’ post-treatment, the observation group had a significant increasing survival rate of 89.13% (41/46), compared to a rate of 71.74% (33/46) in the control group (P <0.05). Conclusion: The combination of anti-PD-1 immunity and surgery following chemotherapy has also been shown to improve the efficacy for athletic patients who have non-small cell lung cancer. It has also been shown to improve immune function and inflammatory responses, lower serum tumor marker levels, and have few adverse reactions; therefore, it is a promising clinical treatment option for promotion and use.